HC Wainwright Weighs in on Longeveron Inc.’s Q1 2024 Earnings (NASDAQ:LGVN)

Longeveron Inc. (NASDAQ:LGVN) – Equities researchers at HC Wainwright issued their Q1 2024 earnings estimates for Longeveron in a research report issued on Monday, April 29th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($1.31) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($10.20) per share. HC Wainwright also issued estimates for Longeveron’s Q2 2024 earnings at ($0.91) EPS, Q3 2024 earnings at ($0.81) EPS, Q4 2024 earnings at ($0.64) EPS, FY2024 earnings at ($3.34) EPS, Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.64) EPS.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($2.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.10) by ($0.40). Longeveron had a negative net margin of 3,020.17% and a negative return on equity of 209.14%. The firm had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.21 million.

Longeveron Trading Up 1.2 %

LGVN opened at $1.71 on Wednesday. Longeveron has a fifty-two week low of $1.60 and a fifty-two week high of $44.00. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.21. The company has a fifty day moving average of $3.62 and a two-hundred day moving average of $10.85.

Institutional Trading of Longeveron

A hedge fund recently bought a new stake in Longeveron stock. Armistice Capital LLC acquired a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 1,836,000 shares of the company’s stock, valued at approximately $2,497,000. Armistice Capital LLC owned approximately 7.31% of Longeveron at the end of the most recent quarter. Institutional investors own 10.01% of the company’s stock.

Insider Transactions at Longeveron

In related news, Director Rock Soffer bought 31,915 shares of the business’s stock in a transaction dated Thursday, April 11th. The stock was acquired at an average price of $2.35 per share, with a total value of $75,000.25. Following the completion of the purchase, the director now directly owns 208,534 shares of the company’s stock, valued at $490,054.90. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Rock Soffer bought 31,915 shares of the business’s stock in a transaction dated Thursday, April 11th. The stock was acquired at an average price of $2.35 per share, with a total value of $75,000.25. Following the completion of the purchase, the director now directly owns 208,534 shares of the company’s stock, valued at $490,054.90. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Joshua Hare bought 106,383 shares of the business’s stock in a transaction dated Wednesday, April 10th. The shares were bought at an average cost of $2.35 per share, with a total value of $250,000.05. Following the purchase, the insider now directly owns 590,727 shares of the company’s stock, valued at $1,388,208.45. The disclosure for this purchase can be found here. Insiders purchased 148,936 shares of company stock valued at $350,000 over the last 90 days. Corporate insiders own 24.34% of the company’s stock.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors.